These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 24530743)
41. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Komatsu E; Yamaguchi F; Abe A; Weiss AA; Watanabe M Clin Vaccine Immunol; 2010 May; 17(5):807-12. PubMed ID: 20357056 [TBL] [Abstract][Full Text] [Related]
42. Prevention of pertussis: An unresolved problem. Esposito S; Principi N Hum Vaccin Immunother; 2018; 14(10):2452-2459. PubMed ID: 29856680 [TBL] [Abstract][Full Text] [Related]
43. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Giuliano M; Mastrantonio P; Giammanco A; Piscitelli A; Salmaso S; Wassilak SG J Pediatr; 1998 Jun; 132(6):983-8. PubMed ID: 9627590 [TBL] [Abstract][Full Text] [Related]
44. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model. Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318 [TBL] [Abstract][Full Text] [Related]
45. [A polyvalent complex of Bordetella pertussis antigens as the basis for an acellular pertussis vaccine]. Zakharova NS; Shmeleva EI; Remova TN; Bazhanova IG; Ozeretskovskaia MN; Mertsalova NU; Britsina MV; Ermolova EV; Zaĭtsev EM Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):70-2. PubMed ID: 9304336 [TBL] [Abstract][Full Text] [Related]
46. Antibody response from whole-cell pertussis vaccine immunized Brazilian children against different strains of Bordetella pertussis. Pereira A; Pietro Pereira AS; Silva CL; de Melo Rocha G; Lebrun I; Sant'Anna OA; Tambourgi DV Am J Trop Med Hyg; 2010 Apr; 82(4):678-82. PubMed ID: 20348518 [TBL] [Abstract][Full Text] [Related]
47. [Immunobiological properties of Bordetella pertussis lipopolysaccharide in the acellular pertussis vaccine]. Zaĭtsev EM; Poddubikov AV; Britsina MV; Mertsalova NU; Ozeretskovskaia MN; Bazhanova IG; Plekhanova NG Zh Mikrobiol Epidemiol Immunobiol; 2014; (1):20-4. PubMed ID: 24738289 [TBL] [Abstract][Full Text] [Related]
50. Identification of immunodominant epitopes in the filamentous hemagglutinin of Bordetella pertussis. Piatti G FEMS Immunol Med Microbiol; 1999 Mar; 23(3):235-41. PubMed ID: 10219596 [TBL] [Abstract][Full Text] [Related]
51. A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against Zurita ME; Wilk MM; Carriquiriborde F; Bartel E; Moreno G; Misiak A; Mills KHG; Hozbor D Front Cell Infect Microbiol; 2019; 9():125. PubMed ID: 31106160 [TBL] [Abstract][Full Text] [Related]
52. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Grimprel E; Bégué P; Anjak I; Njamkepo E; François P; Guiso N Clin Diagn Lab Immunol; 1996 Jan; 3(1):93-7. PubMed ID: 8770511 [TBL] [Abstract][Full Text] [Related]
53. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Storsaeter J; Hallander HO; Gustafsson L; Olin P Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042 [TBL] [Abstract][Full Text] [Related]
54. Investigating pertussis toxin and its impact on vaccination. Coutte L; Locht C Future Microbiol; 2015; 10(2):241-54. PubMed ID: 25689536 [TBL] [Abstract][Full Text] [Related]
55. What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine. Bolotin S; Harvill ET; Crowcroft NS Pathog Dis; 2015 Nov; 73(8):ftv057. PubMed ID: 26253079 [TBL] [Abstract][Full Text] [Related]
56. Resurgence of pertussis calls for re-evaluation of pertussis animal models. van der Ark AA; Hozbor DF; Boog CJ; Metz B; van den Dobbelsteen GP; van Els CA Expert Rev Vaccines; 2012 Sep; 11(9):1121-37. PubMed ID: 23151168 [TBL] [Abstract][Full Text] [Related]
57. Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity. Kerr JR; Matthews RC Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):77-88. PubMed ID: 10746492 [TBL] [Abstract][Full Text] [Related]
58. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. Hellwig SM; Rodriguez ME; Berbers GA; van de Winkel JG; Mooi FR J Infect Dis; 2003 Sep; 188(5):738-42. PubMed ID: 12934190 [TBL] [Abstract][Full Text] [Related]
59. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A; Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665 [TBL] [Abstract][Full Text] [Related]
60. Intranasal Immunization with Acellular Pertussis Vaccines Results in Long-Term Immunity to Bordetella pertussis in Mice. Wolf MA; Boehm DT; DeJong MA; Wong TY; Sen-Kilic E; Hall JM; Blackwood CB; Weaver KL; Kelly CO; Kisamore CA; Bitzer GJ; Bevere JR; Barbier M; Damron FH Infect Immun; 2021 Feb; 89(3):. PubMed ID: 33318136 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]